Explore the potential mechanisms between ertugliflozin and kidney cancer through bioinformatics analysis and Mendelian randomization study
Ertugliflozin may affect kidney cancer by targeting ESR2. SGLT2 inhibition may also be a contributing factor to renal cancer, and further investigation is required.
Authors
- Peng Xiang
- Zunbo He
- Tianqiao Zhang (ORCID: https://orcid.org/0009-0003-4923-5142)
- Xia Yang (ORCID: https://orcid.org/0000-0002-3971-038X)
- Fan Tang
- Jiecan Zhou
- Bo Xu
Institutions
- First Affiliated Hospital of University of South China (CN)
- University of South China (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1097/js9.0000000000004970
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 30.73